Bioptik Technology

Bioptik Technology Receivables

The Accounts Receivable of Bioptik Technology (4161.TWO) as of Nov 4, 2026 is 43.14 M TWD. In the previous year, Accounts Receivable was 66.99 M TWD — a change of -35.61% (lower).

Receivables

43.14 MTWD

YoY

-35.61%

Last updated:

Accounts Receivable of Bioptik Technology is 2024 43.14 M TWD. Accounts Receivable of Bioptik Technology was 2023 66.99 M TWD. It decreases by -35.61% lower compared to the previous year.

The Bioptik Technology Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
55.00 M TWD
Jan 1, 2018
46.53 M TWD
Jan 1, 2019
61.31 M TWD
Jan 1, 2020
46.06 M TWD
Jan 1, 2021
56.99 M TWD
Jan 1, 2022
52.03 M TWD
Jan 1, 2023
66.99 M TWD
Jan 1, 2024
43.14 M TWD
The Bioptik Technology Receivables history
YEARReceivablesYoY
43.14 MTWD-35.61%
66.99 MTWD+28.76%
52.03 MTWD-8.71%
56.99 MTWD+23.73%
46.06 MTWD-24.87%
61.31 MTWD+31.77%
46.53 MTWD-15.40%
55.00 MTWD+23.07%
44.69 MTWD-28.79%
62.76 MTWD+6.69%
58.82 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioptik Technology Stock analysis

What does Bioptik Technology do? Bioptik Technology, Inc. generates revenue through the sale of hyaluronic acid-based skincare products and medical diagnostic equipment. The company sells multifunctional blood sugar, cholesterol, uric acid, and heme detectors under the Easy Mate and Easy Touch brands, along with testing paper products for these parameters. Its cosmetic line, distributed under ACUREAL, includes toning lotions, essences, facial masks, and face cleaning products. Domestic and international markets are the primary sales channels for both product categories. The firm targets healthcare providers and consumers seeking at-home medical monitoring solutions through its Easy Mate and Easy Touch devices. ACUREAL skincare products appeal to customers interested in biological and medical cosmetics for daily skincare routines. Bioptik Technology focuses on the domestic market and overseas markets for product distribution, ensuring broad accessibility across different regions. Easy Mate and Easy Touch are the key medical equipment brands, while ACUREAL represents the cosmetic segment. The company's product portfolio combines medical diagnostics with skincare, serving two distinct consumer segments: health-conscious individuals monitoring vital metrics and users seeking specialized skincare solutions. This dual approach allows Bioptik Technology to leverage its research and development capabilities across both medical and cosmetic applications. Bioptik Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioptik Technology stock

Accounts Receivable of Bioptik Technology is 43.14 M TWD in 2024.

Accounts Receivable of Bioptik Technology changed from 66.99 M TWD to 43.14 M TWD, representing a -35.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Bioptik Technology since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Bioptik Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bioptik Technology

All Key Metrics — Bioptik Technology